These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 2543793)
1. Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. Gould EA; Buckley A J Gen Virol; 1989 Jun; 70 ( Pt 6)():1605-8. PubMed ID: 2543793 [TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated early death in vivo after infection with yellow fever virus. Barrett AD; Gould EA J Gen Virol; 1986 Nov; 67 ( Pt 11)():2539-42. PubMed ID: 3783130 [TBL] [Abstract][Full Text] [Related]
3. Immune enhancement of yellow fever virus neurovirulence for mice: studies of mechanisms involved. Gould EA; Buckley A; Groeger BK; Cane PA; Doenhoff M J Gen Virol; 1987 Dec; 68 ( Pt 12)():3105-12. PubMed ID: 3694178 [TBL] [Abstract][Full Text] [Related]
4. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. Brandriss MW; Schlesinger JJ; Walsh EE; Briselli M J Gen Virol; 1986 Feb; 67 ( Pt 2)():229-34. PubMed ID: 3944585 [TBL] [Abstract][Full Text] [Related]
5. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. Gould EA; Buckley A; Barrett AD; Cammack N J Gen Virol; 1986 Mar; 67 ( Pt 3)():591-5. PubMed ID: 3950582 [TBL] [Abstract][Full Text] [Related]
6. Neurovirulence tests of three 17D yellow fever vaccine strains. Minor PD Biologicals; 2011 May; 39(3):167-70. PubMed ID: 21536454 [TBL] [Abstract][Full Text] [Related]
7. Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. Schlesinger JJ; Chapman S J Gen Virol; 1995 Jan; 76 ( Pt 1)():217-20. PubMed ID: 7844536 [TBL] [Abstract][Full Text] [Related]
8. Neuropathogenesis of Japanese encephalitis virus. Yasui K J Neurovirol; 2002 Dec; 8 Suppl 2():112-4. PubMed ID: 12491161 [TBL] [Abstract][Full Text] [Related]
9. The in vivo differentiation of strains of yellow fever virus in mice. Fitzgeorge R; Bradish CJ J Gen Virol; 1980 Jan; 46(1):1-13. PubMed ID: 6766176 [TBL] [Abstract][Full Text] [Related]
10. Protection of mice against experimental Japanese encephalitis virus infections by neutralizing anti-glycoprotein E monoclonal antibodies. Gupta AK; Lad VJ; Koshy AA Acta Virol; 2003; 47(3):141-5. PubMed ID: 14658841 [TBL] [Abstract][Full Text] [Related]
11. Comparison of neurovirulence of different strains of yellow fever virus in mice. Barrett AD; Gould EA J Gen Virol; 1986 Apr; 67 ( Pt 4)():631-7. PubMed ID: 3958694 [TBL] [Abstract][Full Text] [Related]
12. Neutralization of yellow fever virus studied using monoclonal and polyclonal antibodies. Buckley A; Gould EA J Gen Virol; 1985 Dec; 66 ( Pt 12)():2523-31. PubMed ID: 2999305 [TBL] [Abstract][Full Text] [Related]
13. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers. Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353 [TBL] [Abstract][Full Text] [Related]
14. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. Schlesinger JJ; Brandriss MW; Walsh EE J Immunol; 1985 Oct; 135(4):2805-9. PubMed ID: 4031501 [TBL] [Abstract][Full Text] [Related]
15. The neurovirulence of flaviviruses in crab-eating monkeys (Macaca fascicularis). Angsubhakorn S; Moe JB; Latendresse JR; Ward GS; Ngamprochana M; Sahaphong S; Bhamarapravati N Southeast Asian J Trop Med Public Health; 1986 Dec; 17(4):604-12. PubMed ID: 3033834 [TBL] [Abstract][Full Text] [Related]
16. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893 [TBL] [Abstract][Full Text] [Related]
17. Selection of a neutralization-escape variant strain of Japanese encephalitis virus using monoclonal antibody. Gore MM; Gupta AK; Ayachit VM; Athawale SS; Ghosh SN; Banerjee K Indian J Med Res; 1990 May; 91():231-3. PubMed ID: 1697849 [TBL] [Abstract][Full Text] [Related]
18. Characterization of neutralizing antibodies to West Nile virus. Sánchez MD; Pierson TC; McAllister D; Hanna SL; Puffer BA; Valentine LE; Murtadha MM; Hoxie JA; Doms RW Virology; 2005 May; 336(1):70-82. PubMed ID: 15866072 [TBL] [Abstract][Full Text] [Related]
19. Blood value changes in flavivirus-inoculated Macaca fascicularis monkeys. Angsubhakorn S; Yoksan S; Henchal EA; Nisalak A; Hoke CH; Pradermwong A; Sahaphong S; Bhamarapravati N Southeast Asian J Trop Med Public Health; 1986 Mar; 17(1):1-7. PubMed ID: 2874612 [TBL] [Abstract][Full Text] [Related]
20. Yellow fever vaccine. II. Antigenicity and neurovirulence of a vaccine seed free from avian leukosis virus. Tauraso NM; Spector SL; Kirschstein RL; Seligmann EB; Farber JF Appl Microbiol; 1969 Jun; 17(6):866-70. PubMed ID: 4307883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]